About stephanie.dhont

This author has not yet filled in any details.
So far stephanie.dhont has created 259 blog entries.

February 2023

Genoscience Pharma receives FDA orphan drug designation for ezurpimtrostat to treat hepatocellular carcinoma

2023-02-01T14:21:34+01:00

Genoscience Pharma, supported by MATWIN in 2021, receives FDA orphan [...]

Genoscience Pharma receives FDA orphan drug designation for ezurpimtrostat to treat hepatocellular carcinoma2023-02-01T14:21:34+01:00

January 2023

Brenus Pharma and InSphero receive €1.5 million in grants for the collaborative project “STC-1010”

2023-01-19T15:25:45+01:00

Brenus Pharma, a biotech company specialized in the development of [...]

Brenus Pharma and InSphero receive €1.5 million in grants for the collaborative project “STC-1010”2023-01-19T15:25:45+01:00

EverImmune launches phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer

2023-01-17T12:26:28+01:00

EverImmune supported by MATWIN in 2022 and interviewed by the [...]

EverImmune launches phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer2023-01-17T12:26:28+01:00

MPC Therapeutics announces completion of its CHF 1.5M seed-funding round to improve CAR-T cancer therapies.

2023-01-17T15:31:53+01:00

MPC Therapeutics supported by MATWIN in 2022 and awarded by MATWIN [...]

MPC Therapeutics announces completion of its CHF 1.5M seed-funding round to improve CAR-T cancer therapies.2023-01-17T15:31:53+01:00

Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers

2023-01-17T15:31:41+01:00

Smart Immune supported by MATWIN in 2022 and awarded “ Best Therapeutic Innovation” [...]

Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers2023-01-17T15:31:41+01:00

July 2022

June 2022

Go to Top